Mutant SPTLC1 dominantly inhibits serine palmitoyltransferase activity in vivo and confers an age-dependent neuropathy.

Alexander McCampbell; David Truong; Daniel C Broom; Andrew Allchorne; Ken Gable; Roy G Cutler; Mark P Mattson; Clifford J Woolf; Matthew P Frosch; Jeffrey M Harmon

doi:10.1093/hmg/ddi380

Mutant SPTLC1 dominantly inhibits serine palmitoyltransferase activity in vivo and confers an age-dependent neuropathy.

Identifier:nobleid.org/w1/20260515/50F4CD3A

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/50F4CD3A.svg?ark=w1%2F20260515%2F50F4CD3A)](https://nobleid.org/work/w1/20260515/50F4CD3A)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Mutant SPTLC1 dominantly inhibits serine palmitoyltransferase activity in vivo and confers an age-dependent neuropathy.

Identifier:nobleid.org/w1/20260515/50F4CD3A

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/50F4CD3A.svg?ark=w1%2F20260515%2F50F4CD3A)](https://nobleid.org/work/w1/20260515/50F4CD3A)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work